. 2021 Aug 6;10(9):1065–1072. doi: 10.1530/EC-21-0114
This work is licensed under a Table 1.
Demographic data of the patient sample.
| Total (n = 98) | Graves‘ disease (n = 29) | Goiter or other nodular changes (n = 69) | |
|---|---|---|---|
| Sex | |||
| Male (n; %) | 21 (21.4) | 4 (13.8) | 17 (24.6) |
| Female (n; %) | 77 (78.6) | 25 (86.2) | 52 (75.4) |
| Age, mean (s.d.; range) | 51.2 (14.0; 18–80) | 43.9 (15.3; 18–74) | 54.3 (12.2; 30–80) |
| BMI, mean (s.d.; range) (kg/m²) | 27.9 (5.2; 17.9–44.4) | 27.0 (5.5; 17.9–41) | 28.3 (5.1; 18.4–44.4) |
| Current treatment | |||
| L-thyroxine (n; %) | 9 (9.2) | 0 | 9 (13.0) |
| Antithyroid drugs (n; %) | 34 (34.7) | 28 (96.6) | 6 (8.7) |
| Iodine (n; %) | 3 (3.1) | 0 | 3 (4.3) |
| None (n; %) | 52 (53.1) | 1 (3.4) | 51 (73.9) |
| Preoperative thyroid volumea | |||
| Volume (mL) mean (s.d.; range) | 50.5 (7–380) | 31.1 (7–87) | 59.4 (10–380) |
| Above upper reference value (n; %) | 78 (79.6) | 22 (75.9) | 56 (81.2) |
| Hormonal values | |||
| TSH (µlU/mL) mean (s.d.; range) | 1.3 (1.89; 0–13) | 1.06 (1.99; 0–7.16) | 1.39 (1.86; 0–13) |
| T3 (pg/mL) mean (s.d.; range) | 3.93 (2.50; 0.99–24.42) | 4.33 (1.81; 0.99–8.32) | 3.77 (2.72; 1.79–24.42) |
| T4 (ng/dL) mean (s.d.; range) | 3.68 (5.13; 0.19–25.5) | 3.68 (5.52; 0.51–25.50) | 3.69 (5.02; 0.19–18.72) |
TSH Ref, 0.27–4.20; T3 Ref, 2.57–4.43; T4 Ref, 0.93–1.70.
aData available only for 94 out of 98 patients; normal range for thyroid volume: men < 25 mL; women < 18 mL.